Edition:
India

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.36USD
12:28am IST
Change (% chg)

$0.02 (+5.87%)
Prev Close
$0.34
Open
$0.34
Day's High
$0.37
Day's Low
$0.34
Volume
43,612
Avg. Vol
190,131
52-wk High
$2.13
52-wk Low
$0.28

Select another date:

Mon, Nov 13 2017

BRIEF-Cytori Therapeutics Inc ‍announces new investigator initiated U.S. clinical trial for hip osteonecrosis​

* Cytori Therapeutics Inc - ‍announced a new investigator initiated U.S. clinical trial for hip osteonecrosis​ Source text for Eikon: Further company coverage:

BRIEF-Cytori reports Q3 loss per share $0.14

* Cytori reports third quarter 2017 business and financial results

BRIEF-Cytori Therapeutics enters into an amendment to its existing loan and security agreement

* Cytori Therapeutics- On September 20, 2017, co entered into an amendment to its existing loan and security agreement, dated May 29, 2015 - SEC filing

BRIEF-Cytori announces corporate restructuring & cost reduction plan

* Cytori announces corporate restructuring & cost reduction plan

BRIEF-Cytori Therapeutics Q2 loss per share $0.19

* Cytori reports second quarter 2017 business and financial results

BRIEF-Cytori announces top-line 24- and 48-week results

* Cytori announces top-line 24- and 48-week results from the star trial of habeo cell therapy in patients with scleroderma

BRIEF-AMA approves new category III CPT codes describing Cytori’S Scleroderma therapy

* American Medical Association approves new category III CPT codes describing Cytori’S Scleroderma therapy Source text for Eikon: Further company coverage:

BRIEF-Cytori Therapeutics receives key cell therapy patent for scleroderma

* Cytori Therapeutics - receives key cell therapy patent for scleroderma, patent has a term at least through 2034 Source text for Eikon: Further company coverage:

BRIEF-Cytori Therapeutics announces publication of long-term follow-up data for cancer recurrences following use of Cytori cell therapy

* Cytori Therapeutics announces publication of long-term follow-up data for cancer recurrences following use of Cytori cell therapy

BRIEF-Cytori Therapeutics announces plans to introduce next-gen Celution technology

* Announces plans to introduce its next-generation Celution technology

Select another date: